日本語
IR LIBRARY

IR News

Kubota Pharmaceutical Holdings Co., Ltd.

2026

02/10
Notice regarding Earnings Forecast
01/26
(Progress of Matters Previously Disclosed) Status of Discussions Toward Execution of a License Agreement with Laboratoires KÔL regarding Emixustat Hydrochloride, a Treatment Candidate for Stargardt Disease, at a Consolidated Subsidiary, Kubota Vision Inc.
01/21
Notice regarding the Waiver of Executive Compensation by the Chairman, President & CEO

2025

12/22
(Update on Disclosure Matters) Status of Discussions Toward Execution of a License Agreement with Laboratoires KÔL regarding Emixustat Hydrochloride, a Treatment Candidate for Stargardt Disease, at a Consolidated Subsidiary, Kubota Vision Inc.
12/22
Notice Regarding Completion of Payment for the Issuance of New Shares and 38th Series Stock Acquisition Rights through Third-Party Allotment (in Japanese)
12/19
Amended Securities Registration Statement (in Japanese)
12/19
Extraordinary Report (in Japanese)
12/16
Kubota Pharmaceutical Holdings Announces Initiation of Clinical Trial by the Shanghai Eye Disease Prevention and Treatment Center for Pediatric Myopia Prevention Using "Kubota Glass®"
11/27
Kubota Pharmaceutical Holdings Co., Ltd. Announces Signing of Sales and Distribution Agreements for "Kubota Glass®" with Wuhan Changjiu Vision Health Medical Equipment Co., Ltd. in China
11/17
Capital Increase through Third-Party Allotment and Commercialization of Stargardt Disease Treatment Candidate Emixustat Hydrochloride through the Compassionate Use Program
11/17
Notice Regarding the Issuance of New Shares and 38th Series SARs through TPA, Execution of SAR Purchase Agreement (Commit Issue), Partial Amendment to the Articles, and Changes in Major Shareholders (in Japanese)
11/17
Securities Registration Statement (in Japanese)
11/17
Q3 FY2025 Results Briefing Material
11/14
Consolidated Financial Results for the Nine Months Ended September 30, 2025 (under IFRS)
11/14
Kubota Vision Inc. Signs LOI to Explore Partnership with Laboratoires KÔL for Stargardt Disease Treatment Candidate, including Commercialization Collaboration
11/14
Kubota Pharmaceutical Holdings Announces Technical Service Contract with Shanghai Eye Disease Prevention and Treatment Center for Pediatric Myopia Prevention Using Kubota Glass
11/14
Kubota Pharmaceutical Holdings Co., Ltd. Announces Signing of Sales and Distribution Agreements for "Kubota Glass®" with Shandong Corell Medical Technology Co., Ltd. in China
10/23
Kubota Pharmaceutical Holdings Exhibits at "WOF ASEAN Optical Fair 2025" in Bangkok, Thailand
09/16
Kubota Pharmaceutical Holdings Co., Ltd. Announces Start of "Kubota Glass®" Shipment to End-User in China
09/16
Kubota Pharmaceutical Holdings Co., Ltd. Announces Kubota Glass® at the China International Optics Fair - Exhibition Report (in Japanese)
09/05
Notice of Completion of Exercise and Monthly Exercise Status of the 33rd Stock Acquisition Rights (Third-party Allotment with Exercise Price Revision Clauses) (in Japanese)
09/04
Notice of Large-scale Exercise of the 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/04
Correction: Kubota Pharmaceutical Holdings Co., Ltd. Announces Signing of Sales and Distribution Agreements for "Kubota Glass®" with Fuhao (Shanghai) Optical Technology Co., Ltd. in China (in Japanese)
09/04
Correction: Kubota Pharmaceutical Holdings Co., Ltd. Announces Signing of Sales and Distribution Agreements for "Kubota Glass®" with DuoYuanQiMeng (Beijing) Medical Technology Co., Ltd. in China(in Japanese)
09/02
Notice of Large-scale Exercise of the 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/01
Kubota Pharmaceutical Holdings Co., Ltd. Announces Signing of Sales and Distribution Agreements for "Kubota Glass®" with Fuhao (Shanghai) Optical Technology Co., Ltd. in China(in Japanese)
09/01
Kubota Pharmaceutical Holdings Co., Ltd. Announces Signing of Sales and Distribution Agreements for "Kubota Glass®" with DuoYuanQiMeng (Beijing) Medical Technology Co., Ltd. in China(in Japanese)
09/01
Kubota Pharmaceutical Holdings Co., Ltd. Announces Signing of Sales and Distribution Agreements for "Kubota Glass®" with EverLight Instrument Co., Ltd in Taiwan（in Japanese）
09/01
Update on the Sales Agreement for "Kubota Glass®" with Sakata Pharmaceutical Company
09/01
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses)
08/20
Notice of Termination of the Letter of Intent (LOI) with Sakata Pharmaceutical regarding "Kubota Glass®"
08/14
Notice Regarding the Recognition of the Impairment Loss on Fixed Assets
08/14
Semiannual Report for FY 2025 (in Japanese)
08/14
Q2 FY2025 Results Briefing Material
08/14
Consolidated Financial Results for the Six Months Ended June 30, 2025 (under IFRS)
08/01
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses)
07/31
Notice on Determination of Details of Issuance of Performance-Linked Stock Acquisition Rights (Paid Stock Options) (in Japanese)
07/31
Correction Extraordinary Report (in Japanese)
07/23
Dr. Ryo Kubota, Ophthalmologist & CEO of Kubota Pharmaceutical Delivers Educational Lecture at the 64th Annual Meeting of the Japanese Society for Cataract Research/the 51st Annual Meeting of the Japanese Society for Crystalline Lens Reseah (in Japanese)
07/16
Notice on Issuance of Performance-Linked Stock Acquisition Rights (Paid Stock Options) (in Japanese)
07/16
Extraordinary Report (in Japanese)
07/01
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses)
06/30
Correction Extraordinary Report (in Japanese)
06/27
Notice on Determination of Details of Issuance of Stock Acquisition Rights (in Japanese)
06/20
Notice on Issuance of Stock Acquisition Rights (in Japanese)
06/20
Announcement of Resolution to Propose Issuance of Stock Options (in Japanese)
06/20
Extraordinary Report (in Japanese)
06/02
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses)
05/30
Notice on Cancellation of Stock Acquisition Rights Issuance(in Japanese)
05/21
Notice on Issuance of Stock Acquisition Rights (in Japanese)
05/21
Notice Regarding Suspension of Operations of Consolidated Subsidiary
05/14
Notice Regarding the Recognition of the Impairment Loss on Fixed Assets
05/14
Consolidated Financial Results for the Three Months Ended March 31, 2025 (under IFRS)
05/01
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses)
04/02
Kubota Vision Results on Kubota Glass Technology to be Presented at the ARVO 2025 Annual Meeting
04/01
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses)
03/27
"Kubota Glass" Wins Asia Design Prize 2025 (Winner Award)
03/19
Notice Regarding Appointment of Director Candidates
03/17
Kubota Pharmaceutical Holdings Enters Into a Letter of Intent and Sales Agreement for "Kubota Glass" with Sakata Pharmaceutical Company
03/07
Kubota Vision Announces Issuance of Patent Covering eyeMO from the U.S. Patent and Trademark Office
03/07
Kubota Vision Announces Issuance of Patent Covering Kubota Glass Technology from the Japan Patent Office
03/03
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses)
02/25
FY2024 Financial Results Analyst Meeting presentation
02/25
Kubota Vision Announces Issuance of Patent Covering Kubota Glass Technology from the U.S. Patent and Trademark Office
02/21
Kubota Vision Announces Issuance of Patent Covering VAP-1 Inhibitors from the Japan Patent Office
02/14
Notice Regarding the Recognition of the Impairment Loss on Fixed Assets
02/14
Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 (under IFRS)
02/12
Notice regarding Earnings Forecast
02/03
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses)
01/21
Notice regarding the Waiver of Performance-Based Compensation by the Chairman, President & CEO
01/06
Announcement of the Launch of the Official "Kubota Glass" E-Commerce Site in China
01/06
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)

2024

12/27
Notice regarding the Debt-to-Equity Swap (DES) for the Consolidated Subsidiary
12/24
Notice of Changes to the Service Fees of "Kubota Care" Product Warranty Support for Kubota Glass
12/20
Notice regarding the Termination of Partnership with Sojitz Kyushu Corporation
12/12
Kubota Vision Announces Issuance of Patent Covering VAP-1 Inhibitors
12/02
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
11/29
Notice on Determination of Details of Issuance of Stock Acquisition Rights (in Japanese)
11/21
Kubota Vision Announces Issuance of Patent Covering Kubota Glass Technology
11/20
Announcement of the Relocation and Consolidation of "Kubota Glass" Direct Store
11/14
Consolidated Financial Results for the Nine Months Ended September 30, 2024 (under IFRS)
11/14
Notice on Issuance of Stock Acquisition Rights (in Japanese)
11/01
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/24
Kubota Vision Announces the Initiation of a Specific Clinical Trial Using eyeMO at Shinshu University Hospital
10/03
Kubota Vision Announces Issuance of Patent
10/01
Monthly Update - The 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/12
Kubota Vision Announces Issuance of Patent
09/06
Notice Concerning Expiration of the Exercise Period for the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/05
Notice Concerning Completion of Payment for the 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment (in Japanese)
09/02
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
08/27
FY2024Q2 Financial Results Analyst Meeting presentation
08/20
Notice Concerning Change in Use of Funds for the 33rd Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
08/14
Semiannual Report for FY 2024 (in Japanese)
08/14
Consolidated Financial Results for the Six Months Ended June 30, 2024 (under IFRS)
08/08
Notice regarding Partnership with Sojitz Kyushu Corporation
08/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/25
Kubota Vision Announces Issuance of Patent
07/22
Kubota Pharmaceutical Holdings Co., Ltd. Announces Delivery of "Kubota Glass" to Sojitz Kyushu; Partnership begins to expand sales in China (in Japanese)
07/17
Notice of Decision to Streamline Management by Transferring R&D and Management Bases from the United States to Japan
07/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/06
The Japan Retinitis Pigmentosa Society Submits a Petition to the PMDA, Requesting the Early Approval of Emixustat Hydrochloride, a Potential Treatment Candidate for Stargardt Disease
06/03
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
05/23
Kubota Vision Announces Issuance of Patent
05/14
[Delayed] Consolidated Financial Results for the Three Months Ended March 31, 2024 (under IFRS)
05/14
Quarterly Report for the first quarter of FY2024 (in Japanese)
05/10
Kubota Vision Announces eyeMO Research Presentation at ARVO 2024 Annual Meeting
05/09
Kubota Vision Announces Issuance of Patents
05/07
Kubota Vision Announces CRB Approval for a Specific Clinical Trial Using eyeMO at Shinshu University Hospital
05/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
04/22
Extraordinary Report (in Japanese)
04/22
Resolutions of the Ordinary General Meeting of Shareholders for the Fiscal Year 2023 (in Japanese)
04/22
Extraordinary Report (in Japanese)
04/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
03/29
FY2023 Annual Security Report (in Japanese)
03/29
Business Plan and Matters related to High Growth Potential (in Japanese)
03/21
Partial Correction: Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 (under IFRS)
03/18
Notice Regarding Recording of Impairment Loss on Fixed Assets (in Japanese)
03/06
Correction: Notice regarding Decrease in Capital Amount (Capital Reduction) and Disposal of Other Capital Surplus (in Japanese)
03/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
02/29
Kubota Vision Announces Issuance of Patent
02/27
FY2023 Financial Results Analyst Meeting presentation
02/21
Notice regarding Decrease in Capital Amount (Capital Reduction) and Disposal of Other Capital Surplus (in Japanese)
02/15
Kubota Vision Announces Issuance of Patents
02/14
Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 (under IFRS)
02/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
01/31
Kubota Pharmaceutical Holdings Co., Ltd. Announces Consolidated Earnings Forecasts (in Japanese)
01/05
Kubota Vision Announces Issuance of Patent
01/04
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)

2023

12/25
Kubota Pharmaceutical Holdings Co., Ltd. Announces SUGI+ Haneda Innovation City to Distribute Kubota Glass (in Japanese)
12/06
Kubota Vision Announces Vendor Agreement with IQVIA for eyeMO
12/06
Kubota Vision Announces Agreement with AUROLAB for Development, Manufacturing, Supply, and Distribution License of eyeMO
12/06
Kubota Pharmaceutical Holdings Co., Ltd. Announces Product Name of PBOS as "eyeMO" (in Japanese)
12/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
11/30
Notice on Determination of Details of Issuance of Stock Acquisition Rights (in Japanese)
11/21
Shinagawa Joshi Gakuin Participates in ZERO Diopter Project to Eradicate Myopia (in Japanese)
11/15
Notice on Issuance of Stock Acquisition Rights (in Japanese)
11/14
Quarterly Report for the third quarter of FY2023 (in Japanese)
11/14
Consolidated Financial Results for the Nine Months Ended September 30, 2023 (under IFRS)
11/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/30
Kubota Vision Announces Issuance of Patent
10/26
Japan's First Professional Gamer's College x ZERO Diopter Project to Support Students Who Turn "Love" into "Work" (in Japanese)
10/12
Kubota Vision Announces Issuance of Patents
10/02
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/25
Kubota Pharmaceutical Holdings Co., Ltd. Announces Notice of Establishment of Shareholder Benefit Program (in Japanese)
09/14
Kubota Pharmaceutical Holdings Co., Ltd. Announces Participation of the "i2.JP", Open Innovation Network by AstraZeneca (in Japanese)
09/07
Kubota Vision Announces Collaborative Research Agreement with China Medical University Hsinchu Hospital
09/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
08/31
Kubota Pharmaceutical Holdings Co., Ltd. to Present at Seminar for the Pacific Northwest Chapter of the Society for Information Display
08/30
Kubota Vision Announces Issuance of Patents
08/29
Kubota Pharmaceutical Holdings Co., Ltd. Announces Letter of Intent for Collaboration Opportunities with Sanming City, Fujian Province, China (in Japanese)
08/23
FY2023Q2 Financial Results Analyst Meeting presentation
08/22
Kubota Pharmaceutical Holdings Co., Ltd. Announces Distributor Agreement with Tenryo in Japan
08/21
Kubota Pharmaceutical Holdings Co., Ltd. Announces Initiating Business Verification Project with Rocket Studio, Inc. Using Kubota Glass and Microsoft HoloLens 2
08/10
Quarterly Report for the second quarter of FY2023 (in Japanese)
08/10
Consolidated Financial Results for the Six Months Ended June 30, 2023 (under IFRS)
08/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/21
Kubota Pharmaceutical Holdings Co., Ltd. to Present at the Refractive Surgery Update Seminar 2023 in Kyoto
07/06
Kubota Vision Announces Issuance of Patent
07/03
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/28
Kubota Vision Announces Issuance of Patent
06/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
05/12
Quarterly Report for the first quarter of FY2023 (in Japanese)
05/12
Consolidated Financial Results for the Three Months Ended March 31, 2023 (under IFRS)
05/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
04/24
Resolutions of the Ordinary General Meeting of Shareholders for the Fiscal Year 2022 (in Japanese)
04/24
Extraordinary Report (in Japanese)
04/19
Kubota Vision Announces Issuance of Patents
04/12
Kubota Vision Announces Issuance of Patent
04/05
Kubota Vision Announces Issuance of Patents
04/03
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
03/31
Business Plan and Matters related to High Growth Potential (in Japanese)
03/29
FY2022 Annual Security Report (in Japanese)
03/01
Notice of Partial Amendments to the Articles of Incorporation
03/01
Notice Concerning Personnel Changes of Directors and Executive Officers
03/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
02/21
FY2022 Financial Results Analyst Meeting presentation
02/14
Notice of Recognition of Financial Income, Financial Costs and Other Income (in Japanese)
02/14
Notice of Difference between Earnings Forecast and Actual Results (in Japanese)
02/14
Consolidated Financial Results for the Fiscal Year Ended December 31, 2022 (under IFRS)
02/01
Kubota Pharmaceutical Holdings Co., Ltd. Announces an Update to its Corporate Structure and Transition to a Company with an Audit and Supervisory Committee System
02/01
Kubota Vision Initiates Prospective Study Using Kubota Glass at Kagoshima Sonoda Eye Clinic and Plastic Surgery in Japan
02/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
01/10
Kubota Vision Initiates PBOS Clinical Study in Patients with Diabetic Macular Edema
01/04
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)

2022

12/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
11/24
Correction Extraordinary Report (in Japanese)
11/24
Notice on Determination of Details of Issuance of Stock Acquisition Rights (in Japanese)
11/11
Extraordinary Report (in Japanese)
11/11
Notice on Issuance of Stock Acquisition Rights (in Japanese)
11/11
Quarterly Report for the third quarter of FY2022 (in Japanese)
11/11
Kubota Pharmaceutical Holdings Co., Ltd. Announces Revision of Consolidated Revenue Forecast
11/11
Consolidated Financial Results for the Nine Months Ended September 30, 2022 (under IFRS)
11/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/31
Kubota Pharmaceutical Holdings Co., Ltd. Announces Changes to Contacting Company (in Japanese)
10/14
Notice of Large-scale Exercise of the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/03
Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
10/03
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/29
Kubota Vision Announces Collaboration Agreement with Leading Diabetes Center
09/06
Kubota Vision Announces the Results of Clinical Study in Children Using Wearable Myopia Control Device based on Kubota Glass Technology
09/05
Notice Concerning Completion of Payment for the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment (in Japanese)
08/25
FY2022Q2 Financial Results Analyst Meeting presentation
08/19
Notice Concerning Determination of Terms and Conditions for the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment (in Japanese)
08/19
Correction: Notice Concerning Issuance of the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment and Execution of Third-Party Allotment Agreement (in Japanese)
08/12
Notice Concerning Issuance of the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment and Execution of Third-Party Allotment Agreement (in Japanese)
08/12
Quarterly Report for the second quarter of FY2022 (in Japanese)
08/12
Consolidated Financial Results for the Six Months Ended June 30, 2022 (under IFRS)
08/12
Notice Concerning Change in Use of Funds for the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
08/12
Kubota Vision Announces Top-Line Results from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
08/01
Kubota Vision Announces Kubota Glass Commercialization in Japan (in Japanese)
07/11
Notice Concerning Exercise and Completion of Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/08
Notice of Large-scale Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/07
Notice of Large-scale Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/27
Notice of Large-scale Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/24
Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
06/21
Notice of Large-scale Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/20
Kubota Vision Announces Kubota Glass Commercialization in the U.S.
06/13
Kubota Vision Announces the Registration with the US FDA for Kubota Glass
06/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
05/13
Quarterly Report for the first quarter of FY2022 (in Japanese)
05/13
Supporting Document for the first quarter of FY2022 (in Japanese)
05/13
Consolidated Financial Results for the Three Months Ended March 31, 2022 (under IFRS)
05/02
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
04/25
Resolutions of the Ordinary General Meeting of Shareholders for the Fiscal Year 2021 (in Japanese)
04/25
Extraordinary Report (in Japanese)
04/13
Independent Director Report Submitted to Tokyo Stock Exchange (in Japanese)
04/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
03/29
FY2021 Annual Security Report (in Japanese)
03/15
Notice on Issuance of Stock Acquisition Rights (in Japanese)
03/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
02/18
FY2021 Financial Results Analyst Meeting presentation
02/15
Correction of Consolidated Financial Results for the Fiscal Year Ended December 31, 2020 (under IFRS) (in Japanese)
02/14
Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (under IFRS)
02/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
01/04
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)

2021

12/16
Kubota Pharmaceutical Holdings Co., Ltd. Announces Revision of Consolidated Earnings Forecast
12/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
11/12
Quarterly Report for the third quarter of FY2021 (in Japanese)
11/12
Business Plan and Matters related to High Growth Potential (in Japanese)
11/12
Supporting Document for the third quarter of FY2021 (in Japanese)
11/12
Consolidated Financial Results for the Nine Months Ended September 30, 2021 (under IFRS)
11/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/21
Board Resolution on Selecting Tokyo Stock Exchange's New "Growth Market" Segment (in Japanese)
09/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
08/24
FY2021Q2 Financial Results Analyst Meeting presentation
08/12
Quarterly Report for the second quarter of FY2021 (in Japanese)
08/12
Consolidated Financial Results for the Six Months Ended June 30, 2021 (under IFRS)
08/02
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
05/13
Quarterly Report for the first quarter of FY2021 (in Japanese)
05/13
Supporting Document for the first quarter of FY2021 (in Japanese)
05/13
Consolidated Financial Results for the Three Months Ended March 31, 2021 (under IFRS)
05/06
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
04/26
Resolutions of the Ordinary General Meeting of Shareholders for the Fiscal Year 2020 (in Japanese)
04/26
Extraordinary Report (in Japanese)
04/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
03/29
FY2020 Annual Security Report (in Japanese)
03/18
Notice on Issuance of Stock Acquisition Rights (in Japanese)
03/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
02/24
FY2020 Financial Results Analyst Meeting - recorded video presentation (in Japanese)
02/22
FYE2020 Financial Results Analyst Meeting presentation
02/12
Consolidated Financial Results for the Fiscal Year Ended December 31, 2020 (under IFRS)
02/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)

2020

08/25
FYE2020Q2 Financial Results Analyst Meeting presentation
02/25
FYE2019 Financial Results Analyst Meeting presentation

2019

08/27
FYE2019Q2 Financial Results Analyst Meeting presentation
03/06
FYE2018 Financial Results Analyst Meeting presentation

2018

11/14
FYE2018Q3 Financial Results presentation
08/21
FYE2018Q2 Financial Results Analyst Meeting presentation
05/17
FYE2018Q1 Financial Results presentation
02/21
FYE2017 Financial Results Analyst Meeting presentation

2017

11/22
FYE2017Q3 Financial Results Analyst Meeting presentation
08/23
FYE2017Q2 Financial Results Analyst Meeting presentation
05/18
FYE2017Q1 Financial Results Analyst Meeting presentation
02/21
FYE2016 Financial Results Analyst Meeting presentation

2016

11/15
FYE2016Q3 Financial Results Analyst Meeting presentation
10/21
2016 Annual Event for Shareholders
08/24
FYE2016Q2 Financial Results Analyst Meeting presentation
05/10
FYE2016Q1 Financial Results Analyst Meeting presentation
03/29
FYE2015 Financial Results Analyst Meeting presentation

2015

11/24
FYE2015 3rd Quarter Financial Results Analysts Meeting presentation
08/26
FYE2015 2nd Quarter Financial Results Analysts Meeting presentation
07/01
2015 Annual Event for Shareholders
05/20
Investor Presentation Dated May 20, 2015

2014

11/18
FY2014 3rd Quarter Financial Results Analysts Meeting presentation
09/27
BioCentury "Newsmakers in the Biotech Industry" presentation
08/21
FYE2014 2nd Quarter Financial Results Analysts Meeting presentation
06/11
2014 Annual Shareholder Event
05/21
FYE2014 1st Quarter Financial Results Analysts Meeting presentation
05/07
2014 Proxy Statement
05/07
2013 Annual Report to Stockholders

Acucela Inc.